35 results about "Blood clearance" patented technology

A contrast agent for magnetic resonance imaging having a plurality of nanoparticles. Each of the nanoparticles has: a signal generating core having a diameter of up to 10 nm; at least one organic layer of at least one of a polymer, a monomer, and a surfactant; and a water soluble outer shell of at least one of a polymer, a monomer, and a ligand. The organic layer is adsorbed upon and substantially surrounds and stabilizes the signal generating core. The water soluble outer shell solubilizes and provides biocompatibility for each of the nanoparticles. The contrast agents provide enhanced relaxivity, high signal-to-noise ratios, and targeting abilities. In addition, the contrast agents possess resistance to agglomeration, controlled particle size, blood clearance rate, and biodistribution. Methods of making such contrast agents and nanoparticles are also disclosed.

The invention relates to a long-circulating liposome capable of avoiding an accelerated blood clearance (ABC) phenomenon, a medicine preparation containing the long-circulating liposome, and a preparation method and an application of the long-circulating liposome. The long-circulating liposome provided by the invention comprises phospholipid, auxiliary lipid and poly carboxyl betaine lipid, wherein the long-circulating liposome and the preparation thereof can be applied to medicines for treating related diseases. According to the long-circulating liposome for avoiding the ABC phenomenon provided by the invention, the defect that a common liposome is easily recognized by a reticular endothelium system is overcome; a long-circulating effect of blood is reached; meanwhile, the ABC phenomenon caused by multiple intravenous injections of the PEG-modified long-circulating liposome is avoided; the medicine effect of a therapeutic medicine is effectively improved; and the long-circulating liposome has a high application prospect in the field of medicines.

^99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. ^99mTc-Mito₁₀-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to ^99mTc-MIBI. ^99mTc-Mito₁₀-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.

Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.

The invention discloses an alprostadil lipid nanosphere freeze-drying injection and a preparation method thereof, and belongs to the technical field of medicines. The alprostadil lipid nanosphere freeze-drying injection is prepared from the following raw materials in part by weight: 0.0005 to 0.1 part of alprostadil, 15 to 60 parts of medium-chain oil, 3.0 to 35 parts of emulsifier, 8.5 to 48 parts of polyethylene glycol-12-hydroxy stearate, 22 parts of glycerol, 20 to 200 parts of trehalose, and 20 to 300 parts of cyclodextrin. The particle size of the alprostadil lipid nanosphere freeze-drying injection after redissolution is less than 100nm; and an aseptic filtration way can be used for sterilization, so that the disadvantage of thermal instability of the alprostadil is overcome, and the stability of products is improved. Meanwhile, lipid nanospheres have smaller particle sizes which are less than 100nm, so the alprostadil lipid nanosphere freeze-drying injection is more favorable for the distribution of the alprostadil in in-vivo non-reticuloendothelial system (RES) tissues, reduces pulmonary circulation inactivation and blood clearance, is favorable for circulating in vivo for a long time, and is suitable for the treatment of cardiac and neurosurgical diseases.

The invention relates to a crown ether cyclic quinazoline derivative and medicinal salts thereof using in tumor therapy and imaging. The crown ether cyclic quinazoline compound is characterized in that a 2-, 3-, 4- substituted aniline is disposed at one end; a 6-, 7- substituted crown ether cyclic quinazoline structure is disposed at the other end; the substituent group R1 is located on the fourth-position aniline of a quinazoline mother ring and is 2-, 3-, 4- substituted alkoxy; and the crown ether cycle is located at the 6, 7 position of the mother ring, and is a 9-crown-3, 12-crown-4 and 15-crown-5, and the structural formula is formula I. The experimental result of antitumor activity in vitro of nonradioactive isotope labeling compounds shows that the compounds are good in inhibitory effect for four kind of cancer cells namely HepG2, A549, sy5y and DU145, and have the potential as cancer treatment medicine; and the body distribution experiment of 18F or 125I labeling compounds show that the compounds are higher in ingestion and certain detention in tumors and faster in blood clearance and have potential applied to tumor imaging.

The invention discloses an in-vitro controlled release drug. Red blood cells are used as carriers of the in-vitro controlled release drug, and a target drug and an infrared fluorescent dye are loadedin the red blood cells. By loading the drug in the red blood cells and modifying a photoresponse substance in the red blood cells, after intravenous administration, the targeted release of the targetdrug is realized through the irradiation of laser (808nm) in vitro. The targeted release drug can improve the targeting efficiency of the drug and reduces the blood clearance rate and the poison effect and the like.

The invention discloses a composite cefquinome microsphere gel preparation and a preparation method thereof, and belongs to the technical field of medicines. The composite cefquinome microsphere gel preparation for veterinary use is prepared by adopting a spray drying method to prepare microspheres, adopting cefquinome as the medicine for the microspheres, adopting polylactic acid/polylactic acid-glycolic acid as a coating carrier material, and adopting hyaluronic acid and water as gel bases to prepare the composite cefquinome microsphere gel preparation. The microspheres are of 5-30umd in grain size, which is beneficial to lung targeting of the main medicine cefquinome, the cefquinome can easily gather at a target organ, blood clearance is reduced, long-time circulation is benefited, and pharmacological efficacy is improved. In addition, by the aid of the gel bases, contact of the medicine and interstitial fluid is reduced, the time of the medicine flowing into a bloodstream is prolonged, and a slow-release effect of the preparation is further increased.

Disclosed are an anti-bFGF humanized double-stranded antibody with stable disulfide bond, the preparation method and the applications thereof. The amino acid sequence of the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 1. The nucleotide sequence of gene encoding the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 2. By site-directed mutation, two cysteine residues are introduced into each single-stranded antibody, thus introducing the disulfide bond and form ds-Diabody. It is shown by experiments that the obtained ds-Diabody has the following advantages: enhanced stability; better affinity when binding to the specific antigen bFGF; moderate relative molecular weight, good tumor targeting, more powerful in tumor tissue penetration, and higher blood clearance rate, showing a broad application prospects in the clinic diagnosis and tumor therapy.

A blood-clearing and heart-nourishing tea and a preparation method thereof belong to the field of health-care teas. The following raw materials are included by weight: 4-6 parts of raw Sanqi, 0.5-2 parts of cooked Sanqi, 4-6 parts of Danshen, 8-11 parts of Ganoderma lucidum and 8-11 parts of Burdock. The synergistic effect of each component promotes lipid and sugar metabolism, accelerates cholesterol excretion, reduces cholesterol absorption, and lowers blood viscosity through the three stages of clearing, nourishing, and regulating, so as to reduce blood fat, blood sugar, and blood pressure, and effectively For the purpose of protecting the cardiovascular and cerebrovascular system, the test drinking effect shows that for low-to-medium symptoms of three highs, drinking this tea for three to six months, 70-100% of triglycerides, low-density cholesterol, blood sugar, and blood pressure indicators will return to normal , the inefficiency is below 10%.